Related Experiment Videos
The internist and the vessel wall
1Department of Cardiology, University Hospital, Zürich, Switzerland.
Insights
Atherosclerosis, a key factor in cardiovascular disease, involves endothelial dysfunction and altered L-arginine/nitric oxide (NO) pathways. Therapeutic strategies target platelet activity, lipid levels, and vasoconstriction mechanisms.
Area of Science:
- Cardiovascular Science
- Vascular Biology
- Endothelial Function
Background:
- Atherosclerosis drives end-stage cardiovascular disease through a complex vicious circle.
- Endothelial dysfunction, particularly in the L-arginine/nitric oxide (NO) pathway, is central to atherosclerosis development.
- Associated conditions include diabetes, hyperglycemia, hypertension, and hypercholesterolemia, all impacting endothelial health.
Purpose of the Study:
- To investigate functional changes in the endothelium during atherosclerosis.
- To examine pathological alterations in the L-arginine/nitric oxide (NO) pathway.
- To explore therapeutic targets for normalizing endothelial function.
Main Methods:
- Review of literature on endothelial function and atherosclerosis.
- Analysis of the role of the L-arginine/nitric oxide (NO) pathway.
- Examination of the impact of conditions like diabetes, hypertension, and hypercholesterolemia.
Main Results:
- Alterations in the NO system correlate with abnormal platelet and monocyte interactions.
- Dysfunctional endothelium exhibits abnormal vasoconstriction and structural changes.
- Endothelin, a vasoconstrictor peptide, is upregulated in pathological conditions.
Conclusions:
- Normalizing endothelial function is crucial for managing atherosclerosis.
- Potential therapeutic interventions include platelet inhibitors, lipid-lowering agents, and agents targeting vasoconstriction.
- Novel approaches like endothelin receptor antagonists may offer new treatment avenues.
Abstract:
The essential problem of the vicious circle leading to end-stage cardiovascular disease is atherosclerosis. This paper focuses on the functional changes centred on the endothelium that accompany the development of atherosclerosis, examining in particular pathological alterations in the L-arginine/nitric oxide (NO) pathway. Changes in the NO system are associated with altered platelet and monocyte interactions with the vessel wall, abnormal vasoconstriction and altered vascular structure. Diabetes, hyperglycaemia, hypertension and hypercholesterolaemia are all involved in this process. Endothelin is a vasoconstrictor peptide produced by endothelial cells which is upregulated under these conditions. Normalising endothelial function could involve platelet inhibition, lipid-lowering agents to prevent foam cell formation and decrease the lipid load of the blood vessel wall, and agents to interfere with some of the mechanisms involved in vasoconstriction, proliferation and migration, including ACE-inhibitors and angiotensin receptor antagonists, and possibly new tools such as endothelin receptor antagonists.